Skip to main content
. Author manuscript; available in PMC: 2016 Jan 31.
Published in final edited form as: Prostate. 2014 Oct 13;75(2):191–199. doi: 10.1002/pros.22904

Table 3.

Median PSA (IQR) associated with adverse changes in presenting disease characteristics, JHH PCa MDC 2008–2012

PSA if no PSA if yes p
Gleason up-graded 5.7 (4.3, 9.4) 6.9 (4.7, 21.0) 0.005*
DRE up-staged 5.6 (4.2, 10.0) 6.0 (4.0, 15.1) 0.294*
N0 to N1 6.4 (4.6, 12.6) 12.9 (8.3, 42.9) 0.001*
M0 to M1 6.4 (4.6, 12.1) 31.0 (13.5, 77.9) <0.001*
NCCN risk up-classified 6.5 (4.6, 13.0) 9.7 (5.4, 28.9) *0.007
*

Wilcoxon-Mann-Whitney rank-sum test